How to buy Compugen stock | $6.14

Compugen Ltd is a biotechnology business based in the US. Compugen shares (CGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Compugen employs 68 staff and has a trailing 12-month revenue of around 0.00.

Compugen stock price (NASDAQ: CGEN)

Use our graph to track the performance of CGEN stocks over time.

Compugen shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$6.14
52-week range	$5.76 - $15.16
50-day moving average	$6.34
200-day moving average	$7.26
Wall St. target price	$20.86
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.43

Buy Compugen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Compugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Compugen price performance over time

Historical closes compared with the close of $6.14 from 2021-10-22

1 week (2021-10-15)	-3.46%
1 month (2021-09-24)	-1.29%
3 months (2021-07-23)	-7.95%
6 months (2021-04-23)	-29.67%

1 year (2020-10-23)	-56.64%
2 years (2019-10-24)	45.15%
3 years (2018-10-24)	98.71%
5 years (2016-10-24)	4.07%

Compugen financials

Revenue TTM	$2 million
Gross profit TTM	$1.9 million
Return on assets TTM	-17.34%
Return on equity TTM	-30.68%
Profit margin	0%
Book value	$1.23
Market capitalisation	$538.9 million

TTM: trailing 12 months

Shorting Compugen shares

There are currently 6.4 million Compugen shares held short by investors – that's known as Compugen's "short interest". This figure is 6.8% down from 6.9 million last month.

There are a few different ways that this level of interest in shorting Compugen shares can be evaluated.

Compugen's "short interest ratio" (SIR)

Compugen's "short interest ratio" (SIR) is the quantity of Compugen shares currently shorted divided by the average quantity of Compugen shares traded daily (recently around 617921.44927536). Compugen's SIR currently stands at 10.35. In other words for every 100,000 Compugen shares traded daily on the market, roughly 10350 shares are currently held short.

However Compugen's short interest can also be evaluated against the total number of Compugen shares, or, against the total number of tradable Compugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Compugen's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Compugen shares in existence, roughly 80 shares are currently held short) or 0.0958% of the tradable shares (for every 100,000 tradable Compugen shares, roughly 96 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Compugen.

Find out more about how you can short Compugen stock.

Compugen share dividends

We're not expecting Compugen to pay a dividend over the next 12 months.

Compugen share price volatility

Over the last 12 months, Compugen's shares have ranged in value from as little as $5.76 up to $15.16. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Compugen's is 2.3159. This would suggest that Compugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Compugen overview

Compugen Ltd. , a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd.

Frequently asked questions

What percentage of Compugen is owned by insiders or institutions?
Currently 0.137% of Compugen shares are held by insiders and 45.579% by institutions. How many people work for Compugen?
Latest data suggests 68 work at Compugen. When does the fiscal year end for Compugen?
Compugen's fiscal year ends in December. Where is Compugen based?
Compugen's address is: Building D, Holon, Israel, 5885849 What is Compugen's ISIN number?
Compugen's international securities identification number is: IL0010852080 What is Compugen's CUSIP number?
Compugen's Committee on Uniform Securities Identification Procedures number is: M25722105